scholarly journals Female AhR Knockout Mice Develop a Minor Renal Insufficiency in an Adenine-Diet Model of Chronic Kidney Disease

2020 ◽  
Vol 21 (7) ◽  
pp. 2483 ◽  
Author(s):  
Camélia Makhloufi ◽  
Fanny Nicolas ◽  
Nathalie McKay ◽  
Samantha Fernandez ◽  
Guillaume Hache ◽  
...  

Cardiovascular complications observed in chronic kidney disease (CKD) are associated with aryl hydrocarbon receptor (AhR) activation by tryptophan-derived uremic toxins—mainly indoxyl sulfate (IS). AhR is a ligand-activated transcription factor originally characterized as a receptor of xenobiotics involved in detoxification. The aim of this study was to determine the role of AhR in a CKD mouse model based on an adenine diet. Wild-type (WT) and AhR−/− mice were fed by alternating an adenine-enriched diet and a regular diet for 6 weeks. Our results showed an increased mortality rate of AhR−/− males. AhR−/− females survived and developed a less severe renal insufficiency that WT mice, reflected by urea, creatinine, and IS measurement in serum. The protective effect was related to a decrease of pro-inflammatory and pro-fibrotic gene expression, an attenuation of tubular injury, and a decrease of 2,8-dihydroxyadenine crystal deposition in the kidneys of AhR−/− mice. These mice expressed low levels of xanthine dehydrogenase, which oxidizes adenine into 2,8-dihydroxyadenine, and low levels of the IS metabolism enzymes. In conclusion, the CKD model of adenine diet is not suitable for AhR knockout mice when studying the role of this transcription factor in cardiovascular complications, as observed in human CKD.

2021 ◽  
Vol 25 (6) ◽  
pp. 63-70
Author(s):  
F. U. Dzgoeva ◽  
O. V. Remizov ◽  
V. Kh. Botsieva ◽  
N. G. Malakhova ◽  
Z. R. Ikoeva ◽  
...  

BACKGROUND. Cardiovascular complications caused by vascular calcification in chronic kidney disease (CKD) are closely related to disorders of bone and mineral metabolism, the mechanisms of which require further study.THE AIM: to clarify the role of the regulatory proteins of bone metabolism of sclerostin and osteoprotegerin in the processes of vascular calcification and the development of cardiovascular complications in CKD.PATIENTS AND METHODS. 110 patients with stage 3-5D CKD (67 men) were examined. Median age is 47.0 (23.0-68.0) years. Osteoprotegerin (OPG), sclerostin, intact parathyroid hormone (IPTG), troponin I in blood serum were determined using commercial kits "Enzyme-linked Immunosorbent Assay Kit for Sclerostin" ("Cloud-Clone Corp.", USA) and commercial kits "ELISA kit" ("Biomedica" (Austria) by enzyme immunoassay (ELISA). Echocardiography with Dopplerography was performed on the device "ALOKA 4000" ("Toshiba", Japan). The left ventricular myocardial mass index (LVMI) and peak systolic blood flow velocity in the aortic arch (Vps, peak systolic velocity) were determined to quantify hemodynamic changes indirectly indicating the state of the aortic vascular wall.RESULTS. Analysis of the ratios of the calculated glomerular filtration rate (EGFR), IMLJ, Vps, OPG, and sclerostin showed that a decrease in excretory kidney function is accompanied by an increase in the concentrations of OPG and sclerostin in the blood serum. At the same time, there is an increase in IMLJ and Vps. During the correlation analysis, it was shown that the level of OPG was positively correlated with the level of sclerostin and negatively with the level of iPTG.CONCLUSION. In our study, we obtained data confirming the interactive interaction between the vascular and bone systems. Morphogenetic proteins-inhibitors of bone metabolism (sclerostin and OPG) play a significant role in the defeat of the cardiovascular system in patients with CKD, as they promotes the development of vascular calcification.


2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Jinxiu Hu ◽  
Jiao Qiao ◽  
Qun Yu ◽  
Bing Liu ◽  
Junhui Zhen ◽  
...  

Abstract Background Acute kidney injury (AKI), with a high morbidity and mortality, is recognized as a risk factor for chronic kidney disease (CKD). AKI-CKD transition has been regarded as one of the most pressing unmet needs in renal diseases. Recently, studies have showed that salt inducible kinase 1 (SIK1) plays a role in epithelial-mesenchymal transition (EMT) and inflammation, which are the hallmarks of AKI-CKD transition. However, whether SIK1 is involved in AKI-CKD transition and by what mechanism it regulates AKI-CKD transition remains unknown. Methods We firstly detected the expression of SIK1 in kidney tissues of AKI patients and AKI mice by immunohistochemistry staining, and then we established Aristolochic acid (AA)-induced AKI-CKD transition model in C57BL/6 mice and HK2 cells. Subsequently, we performed immunohistochemistry staining, ELISA, real-time PCR, Western blot, immunofluorescence staining and Transwell assay to explore the role and underlying mechanism of SIK1 on AKI-CKD transition. Results The expression of SIK1 was down-regulated in AKI patients, AKI mice, AA-induced AKI-CKD transition mice, and HK2 cells. Functional analysis revealed that overexpression of SIK1 alleviated AA-induced AKI-CKD transition and HK2 cells injury in vivo and in vitro. Mechanistically, we demonstrated that SIK1 mediated AA-induced AKI-CKD transition by regulating WNT/β-catenin signaling, the canonical pathway involved in EMT, inflammation and renal fibrosis. In addition, we discovered that inhibition of WNT/β-catenin pathway and its downstream transcription factor Twist1 ameliorated HK2 cells injury, delaying the progression of AKI-CKD transition. Conclusions Our study demonstrated, for the first time, a protective role of SIK1 in AKI-CKD transition by regulating WNT/β-catenin signaling pathway and its downstream transcription factor Twist1, which will provide novel insights into the prevention and treatment AKI-CKD transition in the future.


The Clinician ◽  
2021 ◽  
Vol 14 (3-4) ◽  
pp. 78-85
Author(s):  
I. T. Murkamilov

In the development of renocardial relationships in chronic kidney disease, an important role is given to the activation of the renin-angiotensin-aldosterone system (RAAS), as the main component of the progression and development of cardiovascular complications..The presented review is devoted to the analysis of modern scientific data on the effect of high RAAS activity in chronic kidney disease on the course and prognosis of cardiovascular complications, as well as the protective capabilities of angiotensin-converting enzyme inhibitors, in particular perindopril. The results of scientific research on the role of the RAAS in the progression of chronic kidney disease are summarized. Data on chronic kidney disease as a risk factor for cardiovascular and cerebral complications are presented. Attention is focused on the possibilities of prolonging the pre-dialysis period of chronic kidney disease when using angiotensin-converting enzyme inhibitors. The role of perindopril as a lipophilic angiotensin-converting enzyme inhibitor with a high affinity for tissue RAAS was emphasized in reducing cardiovascular and cerebral risk in chronic kidney disease.


2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Sharma Pravesh ◽  
Kalyani Karnam ◽  
Kavita Sedmaki ◽  
Kirti Hira ◽  
Onkar Prakash Kulkarni

Abstract Background and Aims Role of epigenetic factors like histone deacetylases (HDACs) is largely unexplored in the pathogenesis of Nephrocalcinosis-related chronic kidney disease. The present study was performed to evaluate the functional role of HDAC5 in fibroblast activation in in-vitro and in a mouse model of Nephrocalcinosis-related chronic kidney disease. Method C57BL/6 male mice (6-7weeks old) were procured from registered CPCSEA breeder (Hyderabad, India), NRK49F cell line were generously provided by NCCS (Pune, India). All experimental procedures were approved by the animal ethics committee of the institute. Nephrolithiasis (oxalate nephropathy) was induced by feeding oxalate rich diet (Ssniff, Soest, Germany) to C57/BL6 mice for 10 days. NRK49F cells were stimulated with LPS (1µg/ml) for 2hrs followed by TGF-β (25ng/ml) for 24hrs. To achieve HDAC5 knockdown, the cells were pre-incubated with HDAC5 specific siRNA for 24hrs before stimulating with LPS. In another set of experiment, cells were incubated with 4-sodium phenyl butyrate(PBA) a non-selective HDAC5 and HDAC4 inhibitor at a dose of 1mM. 24 hrs after LPS stimulation cell lysates were analysed for protein expression of α-SMA, Collagen1a, KLF2, NLRP3, HDAC5 and β-actin. Mice fed with high oxalate diet were treated with PBA (500mg/kg) twice a day and on day 10 mice were sacrificed to analyse renal function and fibrosis parameters. Mice kidney tissues were analysed for crystal deposition (pizaalato staining), renal fibrosis (Picrosirius staining), and renal histology (H&E staining). The fibrosis markers were analysed by RT-PCR and immunoblotting. Renal function was determined by plasma BUN and creatinine analysis. Diet containing high oxalate with calcium was provided to mice in the control diet group (negative diet control). Results Renal fibroblasts (NRK 49F) stimulated with LPS and TGF-β showed upregulation of HDAC5, NLRP3, α-SMA, and Collagen-1a. Depletion of HDAC5 expression with HDAC5 siRNA significantly reduced expression of NLRP-3, α-SMA, and Collagen-1 in stimulated NRK49F cells. The expression of KLF2 in HDAC5 depleted cells was found to be upregulated. PBA treatment also reduced the expression of HDAC5 in NRK49F cells and had significant reduction in the expression of NLRP3 along with fibroblast activation markers, while KLF-2 expression was found to be up-regulated. Similar to our observation in stimulated renal fibroblasts, the expression of HDAC5 was found to be upregulated in mouse model of oxalate nephropathy. Treatment with PBA showed significant downregulation of HDAC5 in kidneys of the mice fed with high oxalate diet. Mice treated with PBA showed down regulated renal expression of NLRP3, Collagen1a, α-SMA, TGF-β in comparison to vehicle treated mice. Treatment with PBA showed significant upregulation of KLF2 expression in kidney. PBA treated mice showed significant renal protection during nephrolithiasis as indicated by reduced plasma BUN and creatinine levels. Oxalate crystal deposition index was similar in all high oxalate diet groups. PBA treatment showed overall better renal histological protection observed through H&E (reduced tubular injury score) and picrosirius staining (reduced collagen deposition). Conclusion HDAC5 knockdown or HDAC5 inhibition with PBA attenuates fibroblasts activation by inhibiting NLRP3 expression. Treatment with PBA in mice with Nephrocalcinosis-related chronic kidney disease showed significant protection against renal fibrosis with downregulation of NLRP3 expression. We propose HDAC5 as a novel regulator of fibroblast activation in Nephrocalcinosis-related chronic kidney disease.


Sign in / Sign up

Export Citation Format

Share Document